Impact of Helicobacter pylori Infection on the Pathogenesis and Management of Nonalcoholic Fatty Liver Disease

J Clin Transl Hepatol. 2023 Jun 28;11(3):670-674. doi: 10.14218/JCTH.2022.00362. Epub 2023 Jan 19.

Abstract

Helicobacter pylori (H. pylori) infection is widely prevalent worldwide. H. pylori infection has been reported to be a risk factor for the development of insulin resistance, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. Because treatment for NAFLD, other than weight loss is limited, the treatment for H. pylori infection is well established. It is important to determine whether screening and treatment for H. pylori infection should be considered in patients with no gastrointestinal symptoms. The aim of this mini-review is to evaluate the association between H. pylori infection and NAFLD including epidemiology, pathogenesis, and the evidence for H. pylori infection as a modifiable risk factor for preventing or treating NAFLD.

Keywords: Helicobacter pylori; Hepatic fibrosis; Hepatic steatosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

Publication types

  • Review